Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

ASX Announcement – Green Whistle receives regulatory approval in South Africa

Jul 4, 2014AaronNews

Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in South Africa to market and sell its inhaled analgesic product, ‘Penthrox’  for pain relief from trauma and surgical procedures.

The approval gives MVP’s partner in South Africa, LINK Healthcare Pte Ltd (through its wholly owned subsidiary Equity Pharmaceuticals Pty Ltd), the right to start selling ‘Penthrox’ (marketed as ‘Penthrop’ in South Africa) effective immediately. LINK Healthcare estimates the size of the prescription only analgesic market in South Africa is $90 million.

The approval in South Africa opens the regulatory pathway for approvals to sell Penthrox in Namibia, Botswana, Lesotho, Swaziland, Angola, Malawi, Mozambique and Zambia. LINK Healthcare advise the approval process in these countries will take less than 12 months because South African regulators have registered Penthrox for sale.  MVP CEO, Mr. John Sharman said “this approval is a great opportunity for our company and could open the door to Africa”.

Mr. Sharman said “this registration is the first indication we have received that the work done on our clinical trials in England for our regulatory dossier in that country, will enable our company to get approval to sell Penthrox in countries other than the EU where we are currently being assessed.  MVP is in discussion with pharmaceutical companies in various countries in Europe and elsewhere and we are hopeful we can conclude a number of licensing and distribution agreements in the coming months.”

ASX Announcement – Penthrox approved in South Africa

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter